Gene-Editing breakthrough aims to stop sickle cell pain
Disease control
Recruiting now
This study tests a one-time treatment using CRISPR to fix the sickle cell gene in a patient's own blood stem cells. Up to 9 people aged 12 to 35 with severe sickle cell disease will receive the edited cells. The goal is to reduce painful blockages in blood vessels and improve qua…
Phase: PHASE1, PHASE2 • Sponsor: Mark Walters, MD • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC